FibroGen (FGEN) to Release Quarterly Earnings on Tuesday

FibroGen (NASDAQ:FGEN) is scheduled to announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

FibroGen Price Performance

NASDAQ FGEN opened at $0.32 on Friday. The stock’s 50 day simple moving average is $0.37 and its 200 day simple moving average is $0.73. FibroGen has a one year low of $0.29 and a one year high of $2.93. The firm has a market cap of $32.43 million, a PE ratio of -0.19 and a beta of 0.72.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on FibroGen in a report on Wednesday. They set a “hold” rating on the stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.